UBS Group Forecasts Strong Price Appreciation for Addus HomeCare (NASDAQ:ADUS) Stock

Addus HomeCare (NASDAQ:ADUS) had its target price boosted by research analysts at UBS Group from $145.00 to $160.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group‘s price objective would indicate a potential upside of 26.17% from the company’s current price.

A number of other equities research analysts also recently weighed in on ADUS. Barclays raised their price target on shares of Addus HomeCare from $96.00 to $101.00 and gave the company an “underweight” rating in a research note on Wednesday. TD Cowen upped their price objective on shares of Addus HomeCare from $131.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday. Citigroup downgraded shares of Addus HomeCare from a “market outperform” rating to a “neutral” rating in a research note on Monday, September 14th. Weiss Ratings raised shares of Addus HomeCare from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Finally, Royal Bank Of Canada raised their target price on shares of Addus HomeCare from $130.00 to $134.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $134.70.

Addus HomeCare Price Performance

Shares of ADUS stock traded down $1.13 on Thursday, hitting $126.81. 262,556 shares of the company’s stock were exchanged, compared to its average volume of 237,244. The company has a 50 day moving average of $117.35 and a 200 day moving average of $106.71. The stock has a market cap of $2.37 billion, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 1.80 and a beta of 0.75. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.69 and a quick ratio of 1.69. Addus HomeCare has a 12 month low of $87.95 and a 12 month high of $131.59.

Addus HomeCare (NASDAQ:ADUS) last released its earnings results on Tuesday, November 3rd. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. The firm had revenue of $387.74 million for the quarter, compared to analysts’ expectations of $388.72 million. Addus HomeCare had a return on equity of 10.37% and a net margin of 7.39%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.56 earnings per share. On average, equities research analysts predict that Addus HomeCare will post 6.33 EPS for the current year.

Institutional Trading of Addus HomeCare

Several hedge funds and other institutional investors have recently made changes to their positions in ADUS. NFJ Investment Group LLC acquired a new position in shares of Addus HomeCare in the second quarter valued at approximately $29,000. Heritage Family Offices LLP bought a new position in Addus HomeCare in the 3rd quarter valued at approximately $43,000. Parallel Advisors LLC raised its holdings in Addus HomeCare by 66.3% in the 1st quarter. Parallel Advisors LLC now owns 404 shares of the company’s stock valued at $38,000 after buying an additional 161 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Addus HomeCare by 16.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $85,000 after buying an additional 111 shares during the period. Finally, State of Wyoming acquired a new stake in Addus HomeCare during the 2nd quarter worth approximately $79,000. 95.35% of the stock is currently owned by institutional investors.

Key Headlines Impacting Addus HomeCare

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: TD Cowen raised its price target to $145 from $131 and reiterated a Buy rating, implying 14.3% upside from the quoted share price. TD Cowen recommendations
• Positive Sentiment: Third-quarter adjusted EPS of $1.83 topped estimates and rose from $1.56 a year earlier. Revenue increased 7% to $387.7 million, roughly in line with expectations, while adjusted EBITDA grew 13.5% to $51.2 million. Third-quarter earnings
• Positive Sentiment: Addus expects its roughly $275 million acquisition of AccentCare’s personal care division to close in the first quarter of 2027 and anticipates a full-year adjusted EBITDA margin in the 13% range. The deal offers a potential growth opportunity, though integration and closing remain ahead. AccentCare update
• Neutral Sentiment: Medicaid-focused home-care providers could benefit if Medicare for All proposals expand coverage or spending on home- and community-based care. However, the legislation is not imminent, faces political hurdles, and does not guarantee higher provider reimbursement. Healthcare stocks and Medicare for All
• Negative Sentiment: Barclays raised its price target to $101 from $96 but maintained an Underweight rating, indicating a bearish view and substantial downside relative to the quoted share price. Barclays recommendations

Addus HomeCare Company Profile

Addus HomeCare Inc (NASDAQ: ADUS) provides in-home personal care, hospice and home health services to older adults, people with disabilities and other individuals who need assistance with daily living or medical care. Its services are designed to help clients remain safely and independently in their homes while supporting families and caregivers.

The company’s personal care services include assistance with bathing, dressing, grooming, meal preparation, housekeeping and other activities of daily living.